NEW YORK, Aug. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides
http://www.reportlinker.com/p0284636/Triple-Analysis-Lung-Cancer-Cancer-Vaccines-and-Peptides.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Part II: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Part III: Peptides
The peptide report part comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. This report part extensively analyses 125 identified targets of peptide drugs, organized into 103 drug target strategies, and assesses them in 52 different cancer indications.
This part is based on the following publication:
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323
Part II: Cancer Vaccines
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338
9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649
11 Disclaimer 650
12 Drug Index 651
13 Company Index 656
Figures: Includes 6 Figures
Tables: Includes 205 Tables
Total Number of Pages: 659
Part III: Peptides
5.1 The Scope of this Report 24
5.2 The Competitive Advantage and Disadvantage of Peptide Drugs 26
6 Consider the Therapeutic Peptide Target for the Highest Therapeutic Outcome and Return on Investment (125 Drug Targets) 29-219
7 Emerging New Products to Established Ones: Drug Target Strategies of Peptides by their Highest Stage of Development in Oncology (103 Drug Target Strategies and 145 Peptide Drugs) 220-246
8 Selecting Cancer Indications for Peptide Drugs (52 Cancer Indications) 247-300
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (103 Investigators) 301-586
10 Disclaimer 588
11 Drug Index 589
12 Company Index 593
Figures: Includes 4 Figures
Tables: Includes 192 Tables
Total Number of Pages: 596
To order this report:
Drug and Medication Industry: Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article